{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:39:21Z","timestamp":1791920361207,"version":"4.3.4"},"reference-count":70,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Human Papillomavirus is the main cause of cervical cancer, including squamous cell carcinoma of the oropharynx, anus, rectum, penis, vagina, and vulva. In recent years, considerable effort has been made to control HPV-induced diseases using either prophylactic or therapeutic approaches. A critical review of the literature about the therapeutic Human Papillomavirus vaccine was performed to analyze its efficacy in the treatment of female lower genital tract lesions and its possible perspective application in clinical practice. The most important medical databases were consulted, and all papers published from 2000 until 2021 were considered. We retrieved a group of seven papers, reporting the role of anti HPV therapeutic vaccines against the L2 protein in the order of their efficacy and safety in female lower genital tract disease. In addition, the immune response due to vaccine administration was evaluated. The development of therapeutic vaccines represents an interesting challenge for the treatment of HPV infection of the lower genital tract. Literature data underline that the L2 protein may be an interesting and promising target in the development of therapeutic HPV vaccines, but the possible strengths and the unclear longevity of L2 immune responses are factors to be considered before clinical use.<\/jats:p>","DOI":"10.3390\/medicina58070860","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T01:48:38Z","timestamp":1656467318000},"page":"860","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["New Perspectives in Therapeutic Vaccines for HPV: A Critical Review"],"prefix":"10.3390","volume":"58","author":[{"given":"Barbara","family":"Gardella","sequence":"first","affiliation":[{"name":"Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, 27100 Pavia, Italy"},{"name":"Department of Obstetrics and Gynecology, IRCCS Fundation Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gritti","sequence":"additional","affiliation":[{"name":"Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, 27100 Pavia, Italy"},{"name":"Department of Obstetrics and Gynecology, IRCCS Fundation Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8078-5164","authenticated-orcid":false,"given":"Ehsan","family":"Soleymaninejadian","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, IRCCS Fundation Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3744-7888","authenticated-orcid":false,"given":"Marianna","family":"Pasquali","sequence":"additional","affiliation":[{"name":"Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, 27100 Pavia, Italy"},{"name":"Department of Obstetrics and Gynecology, IRCCS Fundation Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3676-7716","authenticated-orcid":false,"given":"Gaetano","family":"Riemma","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, Department of Woman, Child and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6071-0245","authenticated-orcid":false,"given":"Marco","family":"La Verde","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, Department of Woman, Child and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8482-5453","authenticated-orcid":false,"given":"Maria","family":"Schettino","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, Department of Woman, Child and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fortunato","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, Department of Woman, Child and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Torella","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Unit, Department of Woman, Child and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6322-607X","authenticated-orcid":false,"given":"Mattia","family":"Dominoni","sequence":"additional","affiliation":[{"name":"Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, 27100 Pavia, Italy"},{"name":"Department of Obstetrics and Gynecology, IRCCS Fundation Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pvr.2017.12.006","article-title":"Therapeutic vaccines for high-risk HPV-associated diseases","volume":"5","author":"Chabeda","year":"2018","journal-title":"Papillomavirus Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0959-8049(00)00376-2","article-title":"The role of Human Papillomavirus in cervical adenocarcinoma carcinogenesis","volume":"3","author":"Andersson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Graham, S.V. (2017). Keratinocyte Differentiation-Dependent Human Papillomavirus Gene Regulation. Viruses, 9.","DOI":"10.3390\/v9090245"},{"key":"ref_5","unstructured":"World Health Organization (2020). Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem, World Health Organization."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s12033-021-00374-z","article-title":"In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses","volume":"63","author":"Kayyal","year":"2021","journal-title":"Mol. Biotechnol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens\u2014Part B: Biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_8","unstructured":"Human Papillomavirus Vaccines (2009). WHO position paper. Wkly. Epidemiol. Rec., 84, 118\u2013131."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ghelardi, A., Marrai, R., Bogani, G., Sopracordevole, F., Bay, P., Tonetti, A., Lombardi, S., Bertacca, G., and Joura, E.A. (2021). Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease. Vaccines, 9.","DOI":"10.3390\/vaccines9020083"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/jvi.67.1.315-322.1993","article-title":"Self-assembly of Human Papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins","volume":"67","author":"Hagensee","year":"1993","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","article-title":"HPV vaccines\u2014A review of the first decade","volume":"146","author":"Harper","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Olczak, P., and Roden, R.B.S. (2020). Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated Diseases. Vaccines, 8.","DOI":"10.3390\/vaccines8040568"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Rafael, T.S., Rotman, J., Brouwer, O.R., van der Poel, H.G., Mom, C.H., Kenter, G.G., de Gruijl, T.D., and Jordanova, E.S. (2022). Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11041101"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.str.2016.12.001","article-title":"Cryoelectron Microscopy Maps of Human Papillomavirus 16 Reveal L2 Densities and Heparin Binding Site","volume":"25","author":"Guan","year":"2017","journal-title":"Structure"},{"key":"ref_15","first-page":"6032","article-title":"Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding Human Papillomavirus 16\/18 oncoproteins","volume":"63","author":"Davidson","year":"2003","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2886","article-title":"Human Papillomavirus oncoproteins: Pathways to transformation","volume":"10","author":"Moody","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2217\/fmb.10.107","article-title":"Human Papillomavirus: Gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies","volume":"5","author":"Graham","year":"2010","journal-title":"Future Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1038\/s41598-020-62448-3","article-title":"Combination therapy using human papilloma-virus L1\/E6\/E7 genes and archaeosome: A nanovaccine confer immuneadjuvanting effects to fight cervical cancer","volume":"10","author":"Karimi","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.virol.2013.04.017","article-title":"L2, the minor capsid protein of papillomavirus","volume":"445","author":"Wang","year":"2013","journal-title":"Virology"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Keiffer, T.R., Soorya, S., and Sapp, M.J. (2021). Recent Advances in Our Understanding of the Infectious Entry Pathway of Human Papillomavirus Type 16. Microorganisms, 9.","DOI":"10.3390\/microorganisms9102076"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1038\/s41598-021-83076-5","article-title":"High resolution cryo EM analysis of HPV16 identifies minor structural protein L2 and describes capsid flexibility","volume":"11","author":"Goetschius","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e00128-19","DOI":"10.1128\/JVI.00128-19","article-title":"Phosphorylation of Human Papillomavirus Type 16 L2 Contributes to Efficient Virus Infectious Entry","volume":"93","author":"Broniarczyk","year":"2019","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for sys-tematic reviews and meta-analyses: The PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2019). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons. Available online: www.training.cochrane.org\/handbook.","DOI":"10.1002\/9781119536604"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2019). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons. Available online: www.training.cochrane.org\/handbook.","DOI":"10.1002\/9781119536604"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T., Churchill, R., Chandler, J., and Cumpston, M.S. (2019). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons. Available online: www.training.cochrane.org\/handbook.","DOI":"10.1002\/9781119536604"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/S0264-410X(02)00350-X","article-title":"Enhancement of human papillo-mavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine","volume":"20","author":"Khan","year":"2002","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-03-0703","article-title":"Immunological responses in women with Human Papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination","volume":"10","author":"Smyth","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.vaccine.2004.01.049","article-title":"Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16\/18 E6E7)","volume":"22","author":"Davidson","year":"2004","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/ijgc-00009577-200605000-00020","article-title":"Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: Clinical results from a multicenter phase II trial","volume":"16","author":"Fiander","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bjc.6605611","article-title":"Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia","volume":"102","author":"Daayana","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_32","unstructured":"(2022, May 13). Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02405221."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/978-1-4614-0980-9_18","article-title":"The papillomavirus virion: A machine built to hide molecular Achilles\u2019 heels","volume":"726","author":"Buck","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.vaccine.2009.01.102","article-title":"Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20\u201338) peptide displayed on bacterial thioredoxin","volume":"27","author":"Rubio","year":"2009","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1016\/j.vaccine.2014.03.033","article-title":"A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against on-cogenic Human Papillomaviruses","volume":"32","author":"Seitz","year":"2014","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1016\/j.vaccine.2017.07.086","article-title":"Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papil-lomavirus genotypes","volume":"35","author":"Kalnin","year":"2017","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1016\/j.vaccine.2019.06.002","article-title":"A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types","volume":"37","author":"Zhang","year":"2019","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djp106","article-title":"Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillo-mavirus vaccines","volume":"101","author":"Jagu","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1016\/j.vaccine.2010.04.039","article-title":"Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection","volume":"28","author":"Jagu","year":"2010","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e01930-17","DOI":"10.1128\/JVI.01930-17","article-title":"Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses","volume":"92","author":"Pouyanfard","year":"2018","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1158\/1940-6207.CAPR-15-0164","article-title":"Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine","volume":"8","author":"Seitz","year":"2015","journal-title":"Cancer Prev. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"18000","DOI":"10.1038\/s41598-017-18177-1","article-title":"Broadly neutralizing antiviral responses induced by a single-molecule HPV vac-cine based on thermostable thioredoxin-L2 multiepitope nanoparticles","volume":"7","author":"Spagnoli","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/path.2192","article-title":"Integration of high-risk Human Papillomavirus: A key event in cervical carcino-genesis?","volume":"212","author":"Pett","year":"2007","journal-title":"J. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ijc.21394","article-title":"Distinct regu-lation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia","volume":"118","author":"Nijhuis","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1158\/1078-0432.CCR-05-0616","article-title":"Detection of Human Papillomavirus (HPV) 16-specific CD4+ T-cell immunity in pa-tients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment","volume":"11","author":"Kwappenberg","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3389\/fonc.2019.00682","article-title":"Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System","volume":"9","author":"Zhou","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1479-5876-7-108","article-title":"Human Immunodeficiency Virus and Human Papilloma Virus\u2014Why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful","volume":"7","author":"Palefsky","year":"2009","journal-title":"J. Transl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00262-011-1092-5","article-title":"CD4+ T-cell re-sponse against Human Papillomavirus type 16 E6 protein is associated with a favorable clinical trend","volume":"61","author":"Kim","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fimmu.2020.00188","article-title":"The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease","volume":"11","author":"Garbuglia","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/infdis\/jiv753","article-title":"Natural acquired immunity against subsequent genital Human Papillomavirus infection: A systematic review and meta-analysis","volume":"213","author":"Beachler","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fimmu.2019.00008","article-title":"Vaccine strategies to improve anti-cancer cellular immune responses","volume":"10","author":"Vermaelen","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"11120","DOI":"10.1158\/0008-5472.CAN-06-2560","article-title":"Vaccination of healthy volun-teers with Human Papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species","volume":"66","author":"Gambhira","year":"2006","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ijc.21459","article-title":"Detection of Human Papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease","volume":"118","author":"Welters","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"854237","DOI":"10.5402\/2012\/854237","article-title":"CD8 T-cell responses in incident and prevalent Human Papillomavirus types 16 and 18 infections","volume":"2012","author":"Coleman","year":"2012","journal-title":"ISRN Obstet. Gynecol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/0008-5472.CAN-06-3388","article-title":"High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the ab-sence of lymph node metastases in patients with large early-stage cervical cancer","volume":"67","author":"Piersma","year":"2007","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/infdis\/174.5.927","article-title":"The natural history of Human Papillomavirus type 16 capsid antibodies among a cohort of university women","volume":"174","author":"Carter","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/jmv.23664","article-title":"Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women","volume":"85","author":"Tong","year":"2013","journal-title":"J. Med. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/OLQ.0000000000000236","article-title":"A longitudinal study of Human Papillomavirus 16 L1, e6, and e7 seropositivity and oral Human Papillomavirus 16 infection","volume":"42","author":"Beachler","year":"2015","journal-title":"Sex. Transm. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/jnci\/djq384","article-title":"Epidemiologi-cal study of anti-HPV16\/18 seropositivity and subsequent risk of HPV16 and \u221218 infections","volume":"102","author":"Safaeian","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/infdis\/jiu143","article-title":"Naturally acquired immunity against Human Papillomavirus (HPV): Why it matters in the HPV vaccine era","volume":"210","author":"Franceschi","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/infdis\/jiu139","article-title":"Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired Human Papillomavirus type 16\/18 antibodies: Analysis of the control arm of PATRICIA","volume":"210","author":"Naud","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.vaccine.2008.11.099","article-title":"Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity","volume":"27","author":"Karanam","year":"2009","journal-title":"Vaccine"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Huber, B., Wang, J.W., Roden, R.B.S., and Kirnbauer, R. (2021). RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates. J. Clin. Med., 10.","DOI":"10.3390\/jcm10051044"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejpb.2015.05.009","article-title":"Development of a highly thermostable, adjuvanted Human Papillomavirus vaccine","volume":"94","author":"Hassett","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.vaccine.2020.11.066","article-title":"Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists","volume":"39","author":"Zacharia","year":"2021","journal-title":"Vaccine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"LB-200","DOI":"10.1158\/1538-7445.AM2019-LB-200","article-title":"Abstract LB-200: A cGMP-grade chimeric papillomavirus candidate vaccine (HPV16 RG1-VLP) confers long term cross-protection compared to a nonavalent hpv vaccine in a pre-clinical papillomavirus animal model","volume":"79","author":"Hu","year":"2019","journal-title":"Immunology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2045-3701-4-11","article-title":"Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the ab-sence of CD4+ T cells","volume":"4","author":"Peng","year":"2014","journal-title":"Cell Biosci."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Tomai\u0107, V. (2016). Functional Roles of E6 and E7 Oncoproteins in HPV-Induced Malignancies at Diverse Anatomical Sites. Cancers, 8.","DOI":"10.3390\/cancers8100095"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Tumban, E., Peabody, J., Tyler, M., Peabody, D.S., and Chackerian, B. (2012). VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against Human Papillomavirus. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049751"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Yadav, R., Zhai, L., and Tumban, E. (2019). Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?. Viruses, 12.","DOI":"10.3390\/v12010018"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/7\/860\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:39:29Z","timestamp":1760139569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/7\/860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":70,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["medicina58070860"],"URL":"https:\/\/doi.org\/10.3390\/medicina58070860","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]}}}